Use of blood products in sepsis: an evidence-based review.
OBJECTIVE
In 2003, critical care and infectious disease experts representing 11 international organizations developed management guidelines for the use of blood products in sepsis that would be of practical use for the bedside clinician, under the auspices of the Surviving Sepsis Campaign, an international effort to increase awareness and to improve outcome in severe sepsis.


METHODS
The process included a modified Delphi method, a consensus conference, several subsequent smaller meetings of subgroups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee.


METHODS
The modified Delphi methodology used for grading recommendations built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations to contrast adult and pediatric management are in the article by Parker et al. on p. S591.


CONCLUSIONS
In the absence of extenuating circumstances and following resolution of tissue hypoperfusion, red blood cell transfusion should be targeted to maintain hemoglobin at 7.0 g/dL or greater. Erythropoietin is not recommended as a specific treatment for sepsis-associated anemia. Fresh-frozen plasma should be given for documented deficiency of coagulation factors and in the presence of active bleeding or before surgical or invasive procedures. Antithrombin administration is not recommended. Specific platelet transfusion thresholds are based on the presence or absence of bleeding, significant risk for bleeding, plans for surgery or invasive procedures, and platelet count </=5,000/mm.
Zimmerman
Janice L
JL
Baylor College of Medicine, Houston, TX, USA.
D000991:Antithrombins; D016913:Blood Component Transfusion; D003245:Consensus Statements as Topic; D000075202:Contraindications; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000009:adverse effects; D019317:Evidence-Based Medicine; D006801:Humans; D010949:Plasma; D017713:Platelet Transfusion; D017410:Practice Guidelines as Topic; D018805:Sepsis / Q000628:therapy*
D000991:Antithrombins; D004921:Erythropoietin